{"id":2253,"date":"2021-07-27T00:00:00","date_gmt":"2021-07-27T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2253"},"modified":"2021-07-27T00:00:00","modified_gmt":"2021-07-27T00:00:00","slug":"centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/","title":{"rendered":"CENTOGENE mianuje Patrice\u2019a P. Den\u00e8fle\u2019a na stanowisko dyrektora naukowego, kt\u00f3ry b\u0119dzie kierowa\u0107 opartym na danych podej\u015bciem do ponownego odkrywania i rozwoju lek\u00f3w na choroby rzadkie"},"content":{"rendered":"

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) \u2013<\/strong> Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of Dr. Patrice P. Den\u00e8fle as Chief Scientific Officer (CSO). Dr. Den\u00e8fle will join CENTOGENE on August 16, 2021, succeeding Phil Lambert, who has decided to leave the Company.<\/p>\n

Dr. Den\u00e8fle is a seasoned executive and scientific pioneer with over 35 years of experience at pharmaceutical and biotechnology companies in Europe and the U.S. \u2013 spearheading translational R&D to deliver breakthrough treatments to patients. Within his role at CENTOGENE, he will be responsible for overseeing scientific activities to deliver on the Company\u2019s vision and strategy, while driving value creation.<\/p>\n

Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE, said, \u201cWe are truly excited to be bringing Patrice on board. The science of rare diseases is very complex and diverse. Understanding and treating these diseases requires immense expertise across human genetics, functional genomics, multiomic data integration, translational R&D, and molecular pharmacology. Patrice is one of the few people in the industry who has successfully applied unique data-driven approaches to drug discovery and development. With his deep scientific expertise and credentials, as well as his proven industry track record, Patrice will be an outstanding scientific leader for CENTOGENE. He is joining us at an exciting time, as we are now entering our next growth phase with the mission to enable the cure of 100 rare diseases in 10 years. I would also like to acknowledge the work of our outgoing CSO, Phil Lambert, and thank him personally for his significant contributions.\u201d<\/p>\n

\u201cI am a true scientist at heart, and have seen over and over again the power of science to transform medicine and save lives,\u201d added Dr. Den\u00e8fle. \u201cI am impressed by CENTOGENE\u2019s 15 years of scientific innovation and the aggressive growth of its key assets. The Company\u2019s patient-centric Bio\/Databank is uniquely positioned to foster orphan drug development, and I am beyond excited to be joining the team to now harness its potential to reinvent drug discovery and development.\u201d<\/p>\n

Prior to joining CENTOGENE, Dr. Den\u00e8fle served as Chief Scientific Officer at 4P-Pharma, where he led the R&D drug repositioning strategy and operations towards potential full clinical demonstration and asset-value transfer to large pharma companies. Over the past three decades, he has held several leadership positions, including as the General Manager of the Roche Institute for Research and Translational Medicine, as well as other senior roles at Sanofi Aventis and Ipsen. Throughout this time, he has played a key role in translating science into solutions \u2013 helping secure over 300 partnerships and collaborations and initiating countless clinical programs in many disease areas. Dr. Den\u00e8fle also served as CSO at Genethon, a biotech company dedicated to the development of gene therapy treatments for rare diseases. Within these roles, he was always at the forefront of driving biomarker discovery and personalized medicine.<\/p>\n

He received his Ph.D. in Molecular Biology and Biotechnology from the Pasteur Institute, Paris, completed his HDR (Habilitation) in Molecular Pharmacology at the University of Lille, graduated as Adjunct University Professor, and taught Biotechnology for 10 years at the University Paris-Descartes. He was also trained as a CEDEP fellow at INSEAD and has co-authored more than 150 scientific papers and patents.<\/p>\n

O firmie CENTOGENE<\/h2>\n

CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne, genetyczne i multiomiczne w celu diagnozowania, zrozumienia i leczenia chor\u00f3b rzadkich. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych poprzez wykorzystanie naszej rozleg\u0142ej wiedzy i danych na temat chor\u00f3b rzadkich. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 bada\u0144 nad chorobami rzadkimi opart\u0105 na naszym repozytorium danych z rzeczywistego \u015bwiata, obejmuj\u0105cym ponad 3,9 miliarda wa\u017conych punkt\u00f3w danych od oko\u0142o 600 000 pacjent\u00f3w z ponad 120 kraj\u00f3w (stan na 31 grudnia 2020 r.).<\/p>\n

Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi pacjent\u00f3w i kultur kom\u00f3rkowych. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma skoncentrowana na kompleksowej analizie danych wielopoziomowych w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych. Umo\u017cliwia ona lepsz\u0105 identyfikacj\u0119 i stratyfikacj\u0119 pacjent\u00f3w oraz ich chor\u00f3b podstawowych, co umo\u017cliwia i przyspiesza odkrywanie, rozw\u00f3j i dost\u0119p do lek\u00f3w sierocych. Na dzie\u0144 31 grudnia 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z ponad 30 partnerami farmaceutycznymi.<\/p>\n

Wa\u017cna informacja i wy\u0142\u0105czenie odpowiedzialno\u015bci<\/h5>\n

Niniejsza informacja prasowa zawiera stwierdzenia stanowi\u0105ce \u201cstwierdzenia dotycz\u0105ce przysz\u0142o\u015bci\u201d zgodnie z definicj\u0105 tego terminu zawart\u0105 w ameryka\u0144skiej ustawie o reformie przepis\u00f3w procesowych dotycz\u0105cych papier\u00f3w warto\u015bciowych z 1995 r. (Private Securities Litigation Reform Act of 1995), w tym stwierdzenia wyra\u017caj\u0105ce opinie, oczekiwania, przekonania, plany, cele, za\u0142o\u017cenia lub prognozy Sp\u00f3\u0142ki dotycz\u0105ce przysz\u0142ych zdarze\u0144 lub wynik\u00f3w, w przeciwie\u0144stwie do stwierdze\u0144 odzwierciedlaj\u0105cych fakty historyczne. Przyk\u0142adami s\u0105 om\u00f3wienia naszych strategii, plan\u00f3w finansowania, mo\u017cliwo\u015bci rozwoju i wzrostu rynku. W niekt\u00f3rych przypadkach takie stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci mo\u017cna zidentyfikowa\u0107 po terminologii, takiej jak \u201cprzewidywa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cwierzy\u0107\u201d, \u201cszacowa\u0107\u201d, \u201cplanowa\u0107\u201d, \u201cd\u0105\u017cy\u0107\u201d, \u201cprognozowa\u0107\u201d lub \u201coczekiwa\u0107\u201d, \u201cmo\u017ce\u201d, \u201cb\u0119dzie\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cpowinien\u201d \u2013 formy przecz\u0105ce tych termin\u00f3w lub podobne. Stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci oparte s\u0105 na aktualnych przekonaniach i za\u0142o\u017ceniach kierownictwa oraz na informacjach, do kt\u00f3rych Sp\u00f3\u0142ka ma obecnie dost\u0119p. Jednak\u017ce te stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci nie stanowi\u0105 gwarancji naszych wynik\u00f3w i nie nale\u017cy na nich nadmiernie polega\u0107. O\u015bwiadczenia prognostyczne podlegaj\u0105 licznym ryzykom, niepewno\u015bciom i innym zmiennym okoliczno\u015bciom, takim jak niekorzystne warunki gospodarcze na \u015bwiecie oraz ci\u0105g\u0142a niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, wp\u0142yw pandemii COVID-19 na nasz\u0105 dzia\u0142alno\u015b\u0107 i wyniki operacyjne, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i polityce rz\u0105dowej, presja wynikaj\u0105ca z rosn\u0105cej konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zana z uzyskaniem zgody organ\u00f3w regulacyjnych, w tym Ameryka\u0144skiej Agencji ds. \u017bywno\u015bci i Lek\u00f3w (FDA), nasze uzale\u017cnienie od podmiot\u00f3w zewn\u0119trznych i partner\u00f3w, w tym nasza zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasza zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasza zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasza zale\u017cno\u015b\u0107 od kluczowego personelu, nasza zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych lub innymi czynnikami. Takie ryzyka i niepewno\u015bci mog\u0105 spowodowa\u0107, \u017ce o\u015bwiadczenia b\u0119d\u0105 niedok\u0142adne, a czytelnik\u00f3w ostrzega si\u0119 przed nadmiernym poleganiem na takich o\u015bwiadczeniach. Wiele z tych ryzyk jest poza kontrol\u0105 Sp\u00f3\u0142ki i mo\u017ce spowodowa\u0107, \u017ce jej rzeczywiste wyniki b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od tych, kt\u00f3rych si\u0119 spodziewa\u0142a. O\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym s\u0105 aktualne wy\u0142\u0105cznie na dzie\u0144 jego publikacji. Sp\u00f3\u0142ka nie zobowi\u0105zuje si\u0119, a w szczeg\u00f3lno\u015bci nie zobowi\u0105zuje si\u0119 do aktualizacji takich o\u015bwiadcze\u0144 ani do publicznego og\u0142aszania skutk\u00f3w jakichkolwiek zmian w tych o\u015bwiadczeniach w celu odzwierciedlenia przysz\u0142ych zdarze\u0144 lub wydarze\u0144, z wyj\u0105tkiem przypadk\u00f3w wymaganych przez prawo.<\/p>\n

Wi\u0119cej informacji mo\u017cna znale\u017a\u0107 w sekcji \u201eCzynniki ryzyka\u201d w naszym Raporcie Rocznym za rok obrotowy zako\u0144czony 31 grudnia 2020 r., na formularzu 20-F z\u0142o\u017conym w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) 15 kwietnia 2021 r., a tak\u017ce w innych raportach i dokumentach dostarczonych lub z\u0142o\u017conych w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC). Dokumenty te mo\u017cna uzyska\u0107 na stronie EDGAR. na stronie internetowej SEC.<\/a><\/p>\n

Kontakt dla medi\u00f3w:<\/h5>\n

CENTOGENE
Ben Legg
Komunikacja korporacyjna
press@centogene.com<\/a><\/p>\n

Doradztwo FTI
Robert Stanislaro
robert.stanislaro@fticonsulting.com<\/a><\/p>\n

Rachel Kleiman
rachel.kleiman@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2253","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nCENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-27T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development\",\"datePublished\":\"2021-07-27T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/\"},\"wordCount\":1217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/\",\"name\":\"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2021-07-27T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company […]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/","og_site_name":"CENTOGENE","article_published_time":"2021-07-27T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development","datePublished":"2021-07-27T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/"},"wordCount":1217,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/","url":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/","name":"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2021-07-27T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-appoints-patrice-p-denefle-as-chief-scientific-officer-to-lead-its-data-driven-approach-to-reinvent-rare-disease-drug-discovery-and-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Appoints Patrice P. Den\u00e8fle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2253"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}